Avalon GloboCare Corp (AVCO)

Etorro trading 970x250
Avalon GloboCare Corp (AVCO) Logo

About Avalon GloboCare Corp

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People’s Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. In addition, the company develops proprietary diagnostic and therapeutic products leveraging exosome technology; and provides development services for hospitals. The company has a strategic partnership with Weill Cornell Medical College to co-develop bio-production and standardization procedures for chimeric antigen receptor (CAR)-T Therapy; GensKey Medical Technology Co. Ltd. to co-develop and commercialize point-of-care, rapid detection antibody tests to identify whether a patient has been exposed to and has developed antibodies against SARS-CoV-2; GE Healthcare to enhance standardized automation and bio-production for cellular medicines; and HydroPeptide, LLC to co-develop and commercialize various clinical-grade, exosome-based cosmeceutical and orthopedic products, as well as research agreement with Massachusetts Institute of Technology to develop CAR technology. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey. Address: 4400 Route 9 South, Freehold, NJ, United States, 07728

Avalon GloboCare Corp News and around…

Latest news about Avalon GloboCare Corp (AVCO) common stock and company :

NASDAQ Company offers Life Saving Medical Advances; AI & Immunotherapy for Cancer & Immune Related Diseases Including COVID-19: Avalon GloboCare Corp. (NASDAQ: AVCO)
20 Jan, 2022 FinancialContent
NASDAQ Company offers Life Saving Medical Advances; AI and Immunotherapy for Cancer and Immune Related Diseases Including COVID-19: Avalon GloboCare Corp. (NASDAQ: AVCO)
20 Jan, 2022 FinancialContent
Year End Update for this Up & Coming NASDAQ at the forefront of innovations in healthcare Featuring AI & Immunotherapies. Avalon GloboCare Corp. (NASDAQ:AVCO); Is AVCO the Next BFRI?
10 Jan, 2022 FinancialContent
Year End Update for this Up and Coming NASDAQ at the forefront of innovations in healthcare Featuring AI and Immunotherapies. Avalon GloboCare Corp. (NASDAQ:AVCO); Is AVCO the Next BFRI?
10 Jan, 2022 FinancialContent
Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
04 Jan, 2022 Yahoo! Finance

Company continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe Intended SenlangBio acquisition terminated, eliminating potential 80 million share issuance FREEHOLD, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a year-end business update. “We believe we have made significant p

12 Health Care Stocks Moving In Tuesday's Intraday Session
28 Dec, 2021 FinancialContent

Gainers BridgeBio Pharma (NASDAQ:BBIO) shares increased by 17.7% to $13.39 during Tuesday's regular session. Trading ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
23 Dec, 2021 FinancialContent

Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock moved upwards by 27.89% to $1.88 during Thursday's pre-market ...

NASDAQ at the forefront of innovations in healthcare. Avalon GloboCare Corp. (NASDAQ:AVCO): AVCO’s Filtration Tech Could Help Stop Life-Threatening Cytokine Storm in COVID-19 Patients
22 Dec, 2021 FinancialContent
Avalon GloboCare’s Chairman Converts Debt into Common Stock at 45% Premium to Market
22 Dec, 2021 Yahoo! Finance

Avalon’s Chairman converts $3.0 million of debt into common stock at $1.25 per share showing continued confidence and support of the businessFREEHOLD, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the Company’s Chairman, Daniel Lu, has converted $3.0 million of debt owed to him under the Line of Credit into 2.4 million shares of the Company’s com

NASDAQ at the forefront of innovations in healthcare. Avalon GloboCare Corp. (NASDAQ:AVCO): AVCO's Filtration Tech Could Help Stop Life-Threatening Cytokine Storm in COVID-19 Patients
22 Dec, 2021 FinancialContent
12 Health Care Stocks Moving In Thursday's After-Market Session
16 Dec, 2021 FinancialContent

Gainers Eloxx Pharmaceuticals (NASDAQ:ELOX) shares increased by 12.25% to $0.74 during Thursday's after-market ...

NASDAQ Companies Including: Biofrontera (NASDAQ:BFRI), Avalon GloboCare Corp. (NASDAQ:AVCO)
16 Dec, 2021 FinancialContent
NASDAQ Companies Including: Biofrontera (NASDAQ:BFRI), Avalon GloboCare Corp. (NASDAQ:AVCO), Palantir Technologies (NYSE: PLTR) and Nvidia (NVDA) lead the Charge and Artificial Intelligence (AI) is at
16 Dec, 2021 FinancialContent
NASDAQ Company Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development: Avalon Globocare, Inc. (NASDAQ: AVCO)
10 Dec, 2021 FinancialContent
Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development
09 Dec, 2021 Yahoo! Finance

Avalon and research partner, Massachusetts Institute of Technology (MIT), combine their protein design “QTY Code” technology with Google’s DeepMind artificial intelligence (AI) program, AlphaFold2, to accurately predict the 3D structures of protein receptors that have potential use as cellular therapy targetsA study of the application and capabilities of the dual technology was published in the November 2021 issue of Life, a peer-reviewed life sciences journal FREEHOLD, N.J., Dec. 09, 2021 (GLOB

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
07 Dec, 2021 FinancialContent

Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD) stock rose 18.35% to $22.96 during Tuesday's pre-market session. The ...

Shareholders in Avalon GloboCare (NASDAQ:AVCO) are in the red if they invested three years ago
06 Dec, 2021 Yahoo! Finance

If you love investing in stocks you're bound to buy some losers. But long term Avalon GloboCare Corp. ( NASDAQ:AVCO...

20 Stocks Moving in Monday's Pre-Market Session
29 Nov, 2021 FinancialContent

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 85.6% to $3.88 in pre-market trading after jumping 14% on Friday. Petros ...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTS, BRBS, IRT, AVCO, LMRK; Shareholders are Encouraged to Contact the Firm
15 Nov, 2021 Yahoo! Finance

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

This NASDAQ has Life Saving Advances in Today’s Most Critical Bio-Science Fields Planned:
15 Nov, 2021 FinancialContent
Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
14 Oct, 2021 Yahoo! Finance

Co-developed novel technology platform combining S-layer proteins and emulsomes for diverse applications in bio-delivery of drugs and genes with the University of Natural Resources and Life Sciences (BOKU) Vienna FREEHOLD, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced it has successfully co-developed a novel platform of S-layer coated emulsome te

This NASDAQ has Life Saving Advances in Today’s Most Critical Bio-Science Fields of Cancer & Immune Related Disease, Including COVID-19: Avalon GloboCare Corp. (NASDAQ: AVCO)
13 Oct, 2021 FinancialContent
This NASDAQ has Life Saving Advances in Today's Most Critical Bio-Science Fields of Cancer and Immune Related Disease, Including COVID-19: Avalon GloboCare Corp. (NASDAQ: AVCO)
13 Oct, 2021 FinancialContent
Avalon GloboCare's Advanced Filtration Tech Could Help Stop Life-Threatening Cytokine Storm in COVID-19 Patients
07 Oct, 2021 FinancialContent

Image Provided by Pixabay Cytokine storm has made frequent appearances in the news lately as a life-threatening complication in ...

Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases
07 Oct, 2021 Yahoo! Finance

Avalon and research partner, University of Natural Resources and Life Sciences (BOKU), in Vienna, Austria, co-develop a novel technology to efficiently synthesize and study previously difficult to work with drug targets Technology will facilitate drug design for cancer and immune-related diseasesStudy describing the new cell-free, in-silico technology published in September 2021 issue of peer-reviewed journal Membranes FREEHOLD, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NAS

Avalon GloboCare Aims to Revolutionize Cell Therapy Market with a Faster, Safer CAR-T Treatment
30 Sep, 2021 FinancialContent

Image Provided by Pexels With a compound annual growth rate (CAGR) of 34.2%, the global CAR-T cell therapy market is projected to hit ...

Biocept: A New Diagnostic Approach to Improve the Lives of Cancer Patients
29 Sep, 2021 FinancialContent

Battling cancer is often a long journey—and one that becomes even more challenging for the large number of patients who find that ...

Avalon GloboCare to Present at the Benzinga Healthcare Small Cap Conference on September 30th
23 Sep, 2021 FinancialContent
Sysorex Elects Nasdaq-Listed Company CEO William Stilley to Board of Directors
13 Sep, 2021 FinancialContent
INVESTIGATION: Halper Sadeh LLP Investigates INOV, SAFM, LMRK, AVCO, TRIL, XENT; Shareholders are Encouraged to Contact the Firm
09 Sep, 2021 Yahoo! Finance

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Avalon GloboCare Corp (AVCO) is a NASDAQ Common Stock listed in , ,

970x250